On Friday, Shares of The Manitowoc Company, Inc. (NYSE:MTW), dropped -2.86% to $19.39.
The Manitowoc Company, declared recently that it will release its first-quarter 2015 financial results on Wednesday, April 29, after the close of market. The company’s first-quarter results will also be discussed by Manitowoc’s administration team during a live conference call for security analysts and institutional investors, which will be held at 10:00 a.m., Eastern Time, on Thursday, April 30.
The Manitowoc Company, Inc. designs, manufactures, and sells cranes and related products, and foodservice equipment worldwide. The Cranes and Related Products segment offers lattice-boom cranes, counting crawler and truck mounted lattice-boom cranes, and crawler crane attachments.
Shares of Kohl’s Corp. (NYSE:KSS), declined -2.85% to $74.59, during its last trading session.
Kohl’s Corporation, declared an exclusive Gaiam® women’s apparel collection that is now accessible at Kohl’s stores nationwide and Kohls.com. Gaiam (GAIA), a leading innovator in yoga, fitness and well-being, joins Kohl’s growing powerhouse of national active and wellness brands. The new one-of-a-kind Gaiam apparel line balances comfort and style with stay-put designs in yoga specific fabrications, counting hoodies, graphic tops, dresses, skirts, bras, leggings and more, all under $75.
Coinciding with the launch, Kohl’s and Gaiam have partnered with the popular duo, Two Fit Moms, yoga instructors and wellness advocates who are committed to making yoga accessible to people of all fitness levels. These two moms, Laura Kasperzak and Masumi Goldman have lent their expertise to assist perfect the fit, style and performance of the pieces in the collection.
Kohl’s Corporation operates department stores in the United States. It offers private label, exclusive, and national brand apparel, footwear, accessories, beauty, and home products to children, men, and women customers. The company also sells its products online at Kohls.com and through mobile devices.
At the end of Friday’s trade, Shares of ImmunoGen, Inc. (NASDAQ:IMGN), dwindled -2.83% to $9.96.
ImmunoGen, stated financial results for the three-month period ended March 31, 2015 – the third quarter of the Company’s 2015 fiscal year. ImmunoGen also offered an update on its product pipeline and financial guidance.
Pipeline Updates
- Mirvetuximab soravtansine, a potential new therapy for many cases of ovarian cancer in addition to for endometrial cancer and other solid tumors that highly express folate receptor α (FRα); wholly owned by ImmunoGen.
- This ADC now has received orphan designation in ovarian cancer in the EU in addition to in the US.
- Initial findings with mirvetuximab soravtansine – used as a single agent – to treat FRα-positive platinum-resistant ovarian cancer will be presented at the 2015 ASCO Annual Meeting. The data are from a disease-specific Phase 1 cohort. ImmunoGen plans to initiate a Phase 2 trial in this indication by the end of 2015 that could potentially support an accelerated registration pathway.
- ImmunoGen also plans to initiate in 2H2015 assessment of mirvetuximab soravtansine used in combination regimens for ovarian cancer.
- Assessment of mirvetuximab soravtansine for the treatment of FRα-positive relapsed/ refractory (R/R) endometrial cancer is ongoing. ImmunoGen is preparing to also assess it for FRα-positive R/R non-small cell lung cancer.
- In addition to the every three week dosing plan being used in the disease-specific testing underway, dose-finding with a weekly dosing regimen is advancing. The findings to date also have been accepted for presentation at ASCO.
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates comprise IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers.
Finally, Freescale Semiconductor, Ltd. (NYSE:FSL), ended its last trade with -2.80% loss, and closed at $38.86.
Freescale Semiconductor, declared financial results for the first quarter ended April 3, 2015.
First Quarter Highlights
Net sales for the first quarter of 2015 were $1.17 billion, contrast to $1.10 billion in the fourth quarter of 2014 and $1.13 billion in the first quarter of 2014.
Operating earnings for the period were $179 million, contrast to $178 million in the fourth quarter of 2014 and $155 million in the first quarter of 2014. Operating earnings were in line with the preceding quarter. On a year-over-year basis, operating earnings benefitted from higher sales and improving gross margins. Comprised of in first quarter 2015 operating earnings were $26 million of reorganization of business costs, which was an enhance over the preceding quarter and comprised of severance in addition to costs associated with the company’s planned merger with NXP Semiconductors.
Net earnings for the first quarter were $70 million, or $0.22 per share, contrast to net earnings of $63 million, or $0.20 per share, in the fourth quarter of 2014 and a net loss of $23 million, or $(0.08) per share, in the first quarter of 2014. Comprised of in first quarter 2015 net earnings were $21 million of costs associated with the company’s redemption of $250 million of debt securities during the first quarter.
Adjusted operating earnings for the three months ended April 3, 2015 were $234 million contrast to earnings of $211 million in the fourth quarter of 2014 and $186 million in the first quarter of 2014.
Adjusted net earnings for the first quarter of 2015 were $150 million, or $0.48 per share, contrast to $129 million, or $0.42 per share, in the fourth quarter of 2014 and $77 million, or $0.27 per share, in the first quarter of 2014. Adjusted net earnings improved sequentially due to improving sales and higher gross margins. On a year-over-year basis, adjusted net earnings improved due to higher sales, improving gross margins and lower interest expense.
Freescale Semiconductor, Ltd. provides embedded processors worldwide. The company’s products comprise microcontrollers, ranging from 8-bit products to higher performance 16-bit and 32-bit products with on-board flash memory, which provide the digital logic or intelligence for electronic applications and controlling electronic equipment or analyzing sensor inputs.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
